Ilaria Iorillo

Ilaria Iorillo

Auto-generated profile, based on publicly available information

Ilaria Iorillo


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2023 in Respiratory Medicine
Verified
Journal Article
Closed access
APAndrea Portacci
Andrea Portacci
IIIlaria Iorillo
Ilaria Iorillo
Vitaliano Nicola QuarantaVitaliano Nicola Quaranta
Vitaliano Nicola Quaranta
LMLeonardo Maselli
Leonardo Maselli
ELErnesto Lulaj
Ernesto Lulaj
GCGiovanna Elisiana Carpagnano
Giovanna Elisiana Carpagnano

17 April 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GCGiovanna Elisiana Carpagnano
Giovanna Elisiana Carpagnano
APAndrea Portacci
Andrea Portacci
Silvano DragonieriSilvano Dragonieri
Silvano Dragonieri
FMFrancesca Montagnolo
Francesca Montagnolo
IIIlaria Iorillo
Ilaria Iorillo
Vitaliano Nicola QuarantaVitaliano Nicola Quaranta
Vitaliano Nicola Quaranta
Background/Objectives: Several studies have demonstrated the positive clinical and functional impact of adding Long-Acting Muscarinic Antagonist (LAMA) to Inhaled Corticosteroids (ICS) and Long-Acting Beta-Agonists (LABA) therapy in the treatment of severe asthma. Aim and objectives: To demonstrate that treating Small Airways Disease (SAD) in severe asthma patients who are candidates for biologics can improve respiratory symptoms, lung function, and airways inflammation, potentially avoiding or delaying the use of biological therapy. Methods: Thirty-two severe asthma patients with SAD were transitioned from separate inhalers for ICS/LABA and LAMA to extrafine single-inhaler beclomethasone, formoterol, and glycopyrronium. None of these patients underwent biological therapy before the study. Follow-up evaluations were conducted at baseline (T0) and three months after initiation (T3). Assessments included clinical evaluations, spirometry, oscillometry, and inflammation markers. Results: Transitioning to single-inhaler triple therapy from T0 to T3 resulted in significant improvements in Asthma Control Test (ACT) and SAD parameters, including increased Forced Expiratory Volume in the mid-range of lung capacity and improved airway resistance and reactance measurements using impulse oscillometry. A significant reduction in airway inflammation was evidenced by lower levels of Fractional Exhaled Nitric Oxide 350 (FeNO 350) (p < 0.001 for all). Conclusions: Adopting a single-inhaler triple therapy notably enhanced clinical control and small airway function in patients with severe asthma and SAD, supporting the positive impact of target-therapy for the achievement of a stable state termed “Quiet Asthma”.

29 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Vitaliano Nicola QuarantaVitaliano Nicola Quaranta
Vitaliano Nicola Quaranta
APAndrea Portacci
Andrea Portacci
Silvano DragonieriSilvano Dragonieri
Silvano Dragonieri
CLCristian Locorotondo
Cristian Locorotondo
EBEnrico Buonamico
Enrico Buonamico
GCGiovanna Elisiana Carpagnano
Giovanna Elisiana Carpagnano
Introduction: Long COVID is now recognized as a common consequence of the SARS-CoV-2 infection, but we are still far from fully understanding its pathogenesis and predictive factors. Many pathophysiological factors have been studied, including ethnicity. To our knowledge, the risk factors for Long COVID have not been studied in Southeastern Italy. Aims: The aim of this study was to evaluate the predictive factors of Long COVID in a cohort of patients from Southeastern Italy. Methods: We conducted a retrospective longitudinal study, enrolling inpatients and outpatients diagnosed with COVID-19 from June 2021 to March 2022. A total of 436 subjects were evaluated in an outpatient setting 12 weeks after a SARS-CoV-2 infection, recording comorbidities, symptoms, therapy, and clinical information. Univariate and multivariate binomial logistic regression analyses were performed on different risk factors to define the probability of developing Long COVID. Results: A total of 71.8% of patients (313) developed Long COVID, while the remaining 123 (28.3%) had a complete remission of symptoms 3 months after acute infection. During the acute phase of COVID-19, 68.3% of patients experienced respiratory failure and 81.4% received corticosteroid therapy. In a multivariate analysis, the female sex (SEX M ODD 0.513) and corticosteroids (ODD 2.25) were maintained as predictive values. Conclusions: From our data and in line with other studies, the female sex emerges as a risk factor for Long COVID in the population of Southeastern Italy. Corticosteroid therapy administered in the acute phase also appears to be associated with an increased risk of Long COVID. Although indications for the prescription of corticosteroid therapy in the acute phase were indicated by the presence of pneumonia complicated by respiratory insufficiency, there was an over-prescription of corticosteroid therapy in the real life of our cohort, with 64% of patients having respiratory insufficiency and 81% having corticosteroid therapy. We hypothesize that a synergistic link between viral infection and the side effects of corticosteroid therapy may arise in selected cases.

Verified
Journal Article
Open access
PDF file
APAndrea Portacci
Andrea Portacci
IIIlaria Iorillo
Ilaria Iorillo
LMLeonardo Maselli
Leonardo Maselli
MAMonica Amendolara
Monica Amendolara
Vitaliano Nicola QuarantaVitaliano Nicola Quaranta
Vitaliano Nicola Quaranta
GCGiovanna Elisiana Carpagnano
Giovanna Elisiana Carpagnano
Galectins are a group of β-galactoside-binding proteins with several roles in immune response, cellular adhesion, and inflammation development. Current evidence suggest that these proteins could play a crucial role in many respiratory diseases such as pulmonary fibrosis, lung cancer, and respiratory infections. From this standpoint, an increasing body of evidence have recognized galectins as potential biomarkers involved in several aspects of asthma pathophysiology. Among them, galectin-3 (Gal-3), galectin-9 (Gal-9), and galectin-10 (Gal-10) are the most extensively studied in human and animal asthma models. These galectins can affect T helper 2 (Th2) and non-Th2 inflammation, mucus production, airway responsiveness, and bronchial remodeling. Nevertheless, while higher Gal-3 and Gal-9 concentrations are associated with a stronger degree of Th-2 phlogosis, Gal-10, which forms Charcot–Leyden Crystals (CLCs), correlates with sputum eosinophilic count, interleukin-5 (IL-5) production, and immunoglobulin E (IgE) secretion. Finally, several galectins have shown potential in clinical response monitoring after inhaled corticosteroids (ICS) and biologic therapies, confirming their potential role as reliable biomarkers in patients with asthma.

12 April 2024 in Respiratory Medicine
Verified
Journal Article
Closed access
APAndrea Portacci
Andrea Portacci
MAMonica Amendolara
Monica Amendolara
Vitaliano Nicola QuarantaVitaliano Nicola Quaranta
Vitaliano Nicola Quaranta
IIIlaria Iorillo
Ilaria Iorillo
EBEnrico Buonamico
Enrico Buonamico
GCGiovanna Elisiana Carpagnano
Giovanna Elisiana Carpagnano

22 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Vitaliano Nicola QuarantaVitaliano Nicola Quaranta
Vitaliano Nicola Quaranta
APAndrea Portacci
Andrea Portacci
FMFrancesca Montagnolo
Francesca Montagnolo
Silvano DragonieriSilvano Dragonieri
Silvano Dragonieri
IIIlaria Iorillo
Ilaria Iorillo
GCGiovanna Elisiana Carpagnano
Giovanna Elisiana Carpagnano
Background/Objective: Patients with severe asthma (SA) and non-cystic fibrosis bronchiectasis (BE) without microbiological colonization represent a unique and understudied population. Type 2-targeted biologic therapies have emerged as a promising treatment for these patients. However, predictive factors for achieving clinical remission remain unclear. This study aims to identify the predictive factors for achieving clinical remission in patients with severe asthma and non-colonized bronchiectasis undergoing type 2-targeted biologic therapies. Methods: A retrospective longitudinal analysis was conducted on 14 patients with severe asthma and non-cystic fibrosis bronchiectasis without microbiological colonization. Clinical remission was assessed at baseline (T0) and after 12 months (T1) of biologic therapy. Clinical remission was defined according to the Severe Asthma Network Italy (SANI) criteria, including the absence of oral corticosteroid use, no asthma-related symptoms, stable lung function, and no exacerbations. Logistic regression was performed to identify predictors of remission. ROC curves were constructed to evaluate the predictive accuracy of lung function parameters, specifically FEV1 and FVC. Results: After 12 months of biologic therapy, 28.6% of patients (n = 4) achieved clinical remission. The mean FEV1 percentage at baseline was significantly higher in the remission group (92.25 ± 15.64%) compared to the non-remission group (65.10 ± 23.36%, p = 0.034). Logistic regression analysis identified baseline FEV1 as a significant predictor of remission (OR = 1.008, p = 0.050). ROC curve analysis revealed that an FEV1 cutoff of 72.5% had a sensitivity of 100% and a specificity of 70% (AUC = 0.900, p = 0.024) for predicting clinical remission. Conclusions: FEV1 is a crucial predictor of clinical remission in patients with severe asthma and non-colonized bronchiectasis treated with type 2-targeted biologic therapies. An FEV1 threshold of 72.5% can guide clinicians in identifying patients most likely to achieve remission. These findings underline the importance of preserving lung function to optimize therapeutic outcomes in this complex population.